PURPOSE: To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFalpha agent. DESIGN: Single interventional case report. METHODS: A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab (Remicade, Centocor) treatment for Ankylosing spondylitis (AS) as part of the open-label phase of a trial conducted at our tertiary referral center. Cultures grew Staphylococcus aureus. RESULTS: Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy. Infliximab therapy was resumed after three weeks. CONCLUSIONS: Clinical vigilance is warranted when treating patients with anti-TNFalpha agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.

Adult↗

PubMed2005

Glycogen storage diseases and cardiomyopathy.

Explore the source record for details and available documents.

AMP-Activated Protein Kinases↗

PubMed2005

Use of trypan blue for penetrating keratoplasty.

Use of trypan blue for penetrating keratoplasty was developed to facilitate the procedure. Trypan blue is injected before and after the addition of 0.25 mL of an ophthalmic viscosurgical device (OVD), sodium hyaluronate, to stain the internal and external cut edge of the cornea as well as the OVD, enabling the surgeon to improve visualization of the incision and suture depth, improve alignment of host and donor tissues, and ensure that all OVD is removed.

Coloring Agents↗